Site Search
Professionals 783 results
Capabilities 88 results
Practice Area
Trial skills matter—even in a world where few disputes ever see the inside of a courtroom. Winston has built a reputation as a trial lawyers’ firm, featuring seasoned litigators who leverage extensive courtroom experience to meet our clients’ business and legal objectives. Our long history of taking cases to trial—and winning—provides our clients with tremendous settlement leverage with their adversaries, as well as a substantial likelihood of a favorable resolution if, and when, they go to trial.
Practice Area
For decades, Winston has represented a broad array of clients in the insurance industry, including some of the world’s largest and best-known insurers. Our prowess in and understanding of the insurance industry encompasses not only its products, practices, and services, but also the increasing challenges posed by a world increasingly characterized by a fast-evolving technological landscape as well as financial, political, and environmental instability. Accordingly, Winston’s lawyers are among the most sought-after in the industry—not only by companies currently facing high-stakes litigations and investigations, but by those looking to take preventive action now in order to mitigate and manage their risk in the future.
Practice Area
Securities, M&A & Corporate Governance Litigation
In today’s market, litigators with experience in securities, corporate governance, and M&A-related (collectively, “securities litigation”) matters need to leverage their broad experience to serve as both advocate and as counsel and strategist, focused on helping clients to overcome not just a legal issue but a collective business problem. Given the frequent interplay between things such as corporate-control transactions, public offerings, activist shareholders, the use of complex derivatives and other financial instruments, bad news impacting stock performance, regulatory inquiries and investigations, and insurance coverage, strategic and tactical litigation decisions can have a wide-ranging impact on the success of a given transaction, as well as on companies, their boards, senior management, and advisors.
Experience 76 results
Experience
|September 8, 2025
Winston represents a class of professional swimmers alleging World Aquatics (WA) violated antitrust laws by blocking their participation in the competing International Swimming League. After WA won summary judgment, Winston successfully appealed, arguing the court applied improper antitrust standards and wrongly denied certification of a damages class. In September 2024, the Ninth Circuit reversed both rulings, reviving all claims and issuing a landmark ruling on the possible application of the per se rule or quick look review to sports-associations rules. Am Law awarded Winston “Litigator of the Week” Runner-Up recognition for the win. In November 2024, the Ninth Circuit denied rehearing. In April 2025, the district court certified a damages class.
Experience
|July 30, 2025
Represent Norman W. Fries, Inc. d/b/a Claxton Poultry Farms in a series of 15+ antitrust class actions consolidated in the Northern District of Illinois and brought by plaintiffs who allege that Claxton and the nation’s other largest poultry producers conspired to fix the price of broiler chickens in a scheme from 2008 to 2016 that raised the price for broiler chickens by artificially reducing supply.
Experience
|July 17, 2025
D. Boral Capital Closes US$15M Robot Consulting IPO
Winston & Strawn LLP represented D. Boral Capital LLC and Craft Capital Management LLC in connection with the US$15M initial public offering of American Depositary Shares (ADSs) of Robot Consulting Co., Ltd. The offering consisted of 3,750,000 ADSs priced at $4.00 per ADS, and the company’s ADSs began trading on the Nasdaq Capital Market under the ticker symbol “LAWR” on July 17, 2025.
Insights & News 5,026 results
Recognitions
|October 31, 2025
|1 Min Read
Winston & Strawn Ranked in 2025 Chambers Brazil: Transactional Guide
Winston & Strawn has been recognized in the 2025 edition of Chambers Brazil: Transactional Guide. Chambers Brazil ranks and reviews the top law firms and lawyers in Brazil based on in-depth research and client feedback across key practice areas and industry sectors. The firm was ranked for its strength in the following international firm practice areas:
Recognitions
|October 30, 2025
|Less Than 1 Min Read
Winston & Strawn Recognized in 2026 Benchmark Litigation
Winston & Strawn has been recognized in the 2026 edition of Benchmark Litigation, which covers the litigation and disputes market in North America. The firm is recognized for its excellence in litigation in the following categories:
False Claims Act Playbook
|October 30, 2025
|5 Min Read
On October 15, 2025, the United States District Court for the District of Nebraska (the Court) dismissed Pharos Capital Group and its related investment funds (Pharos Capital) from a qui tam or whistleblower suit brought under the antiretaliation provision of the False Claims Act (31 U.S.C. § 3730(h)) (the FCA), against Pharos Capital and Charter Health Care Group (Charter), a portfolio company of Pharos Capital.
Other Results 116 results
Law Glossary
What Is Advertising Litigation?
Advertising litigation is defined as the legal area that covers false or deceptive advertising cases. Lawsuits may be brought by government agencies or corporate competitors based on the Lanham Act—a law that specifically deals with false advertising. The Act outlines how an advertisement can be deemed false. The Federal Trade Commission (FTC) has the ability to file lawsuits to halt deceptive advertising claims. The U.S. Food and Drug Administration may also pursue advertising litigation against violators of government regulations. Companies may be called on to substantiate their advertising claims, whether these are made in print or online.
Law Glossary
What Are the Patent Litigation Differences Between the BPCIA and Hatch-Waxman Act?
There are fundamental differences between the abbreviated approval processes to obtain FDA approval for biosimilars and generic drugs as those processes relate to patent litigation.